Evidence map›Paper›PMID 35501823›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.

Qingxin Fan, Jing Zuo, Hailong Tian, Canhua Huang, Edouard C Nice, Zheng Shi, Qingquan Kong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Qingxin Fan *Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.), Sichuan University, Chengdu, 610041, China.
Jing Zuo *Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.), Sichuan University, Chengdu, 610041, China.
Hailong Tian *Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.), Sichuan University, Chengdu, 610041, China.
Canhua HuangState Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.
Edouard C NiceDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia.
Zheng ShiClinical Medical College &, Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, 610106, China. shizheng@cdu.edu.cn.
Qingquan KongDepartment of Orthopedics, Hospital of Chengdu Office of People's Government of TibetanAutonomous Region (Hospital.C.T.), Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, China. kqqspine@126.com.
Sichuan University · CNChengdu University · CNMonash University · AU

Funding

1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University ZYJC210261·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University ZYJC21077Chengdu Science and Technology Program 2019-YF05-00715-SNGuangdong Basic and Applied Basic Research Foundation 2019B030302012National Key Research and Development Project 2020YFA0509400National Natural Science Foundation of China 81171731National Natural Science Foundation of China 81790251National Natural Science Foundation of China 81821002National Natural Science Foundation of China 82130082Science and Technology Project of Tibet Autonomous Region XZ201901-GB-08Science and Technology Project of Tibet Autonomous Region XZ202101ZR0112GSichuan Science and Technology Program 2020YFQ0007Sichuan Science and Technology Program 2020YFS0080Sichuan Science and Technology Program 2021JDRC0159the Project of the Hospital of Chengdu Office of the People's Government of the Tibet Autonomous Region 2020-YJYB-1
6 · The paper itself

Abstract

backgroundThe high postoperative recurrence rate and refractoriness of relapsed tumors are still a conundrum for the clinical management of osteosarcoma (OS). New therapeutic options are urgently needed. Depriving the nourishment of myeloid-derived suppressor cells is a novel strategy to improve the immunosuppressive tumor microenvironment for enhanced OS therapy.

methodsWe synthesized a hyaluronic acid (HA)-modified metal-organic framework for combinational chemotherapy and immunotherapy of OS. Zeolitic Imidazolate Framework-8 (ZIF-8) was prepared by a one-pot synthetic method, Gemcitabine (Gem) and D-1-Methyltryptophan (D-1-MT) were loaded into the ZIF-8 during the synthesis process to make ZIF-8@Gem/D-1-MT nanoparticles (NPs). The end product (HA/ZIF-8@Gem/D-1-MT NPs) was obtained by HA modification on the surface of ZIF-8@Gem/D-1-MT NPs. The obtained HA/ZIF-8@Gem/D-1-MT NPs have excellent potential as a drug delivery vector for chemotherapy and immunotherapy in vitro and vivo.

resultsThe results indicate that HA/ZIF-8@Gem/D-1-MT NPs were readily taken up by OS cells, and that the Gem and D-1-MT were effectively released into the acidic environment. The HA/ZIF-8@Gem/D-1-MT NPs could efficiently decrease OS cell viability (proliferation, apoptosis, cell cycle, migration and invasion). And HA/ZIF-8@Gem/D-1-MT NPs could reactivate antitumor immunity by inhibiting indoleamine 2,3 dioxygenase and myeloid-derived suppressor cells. Furthermore, animal experiments confirmed that HA/ZIF-8@Gem/D-1-MT NPs could induce intratumoral immune responses and inhibit tumor growth. Additionally, HA/ZIF-8@Gem/D-1-MT NPs have a good safety profile.

conclusionsOur findings demonstrate that the combination of Gem with D-1-MT brings new hope for the improved treatment of OS, while the generation of the nanosystem has increased the application potential and flexibility of this strategy.

Indexed as

Bone NeoplasmsDioxygenasesMetal-Organic FrameworksMyeloid-Derived Suppressor CellsOsteosarcomaZeolitesAnimalsHumansImmunotherapyTumor MicroenvironmentDioxygenasesMetal-Organic FrameworksZeolitesChemotherapyImmunotherapyMetal organic frameworkNanosystemOsteosarcoma

Identifiers

PMID35501823
PMCPMC9063269
OpenAlexW4225377298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.